Evolus EBITDA 2016-2025 | EOLS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Evolus ebitda from 2016 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Evolus ebitda from 2016 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$229B
Boston Scientific (BSX)	$157.6B
Stryker (SYK)	$150.8B
EssilorLuxottica (ESLOY)	$144B
Medtronic (MDT)	$118.3B
Lonza Group Ag (LZAGY)	$50.6B
Haleon (HLN)	$43.2B
ResMed (RMD)	$41.8B
GE HealthCare Technologies (GEHC)	$33.8B
Agilent Technologies (A)	$33.6B
Koninklijke Philips (PHG)	$26.8B
Terumo (TRUMY)	$26.5B
Insulet (PODD)	$23.4B
Zimmer Biomet Holdings (ZBH)	$21.3B
Smith & Nephew SNATS (SNN)	$16.3B
Baxter (BAX)	$12.6B
Sunny Optical Technology (SNPTF)	$10.8B
Demant (WILYY)	$8.1B
Bio-Rad Laboratories (BIO)	$8B
Lantheus Holdings (LNTH)	$3.8B
Envista Holdings (NVST)	$3.5B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Prestige Consumer Healthcare (PBH)	$3.3B
Perrigo (PRGO)	$3.3B
ICU Medical (ICUI)	$3.1B
Haemonetics (HAE)	$2.7B
LeMaitre Vascular (LMAT)	$2.2B
Acuren (TIC)	$2.2B
Curaleaf Holdings (CURLF)	$2.1B
QuidelOrtho (QDEL)	$1.9B